Steven K Macleod

US Patent:

7387623, Jun 17, 2008

Filed:

Aug 20, 2003

Appl. No.:

10/644516

Inventors:

Steven K. MacLeod - Portage MI, US

Assignee:

Pfizer Inc. - New York NY

International Classification:

A61B 19/00
B65D 81/32

US Classification:

604416, 215 6, 206219

Abstract:

An article of manufacture is provided comprising a vial having (a) a first chamber that is substantially filled with an injectable pharmaceutical formulation; (b) a second chamber that is substantially empty but for a gaseous medium; (c) a septum, impermeable to the gaseous medium, separating the first and second chambers; and (d) actuating means effective to bring the formulation and the gaseous medium into contact by breach of the septum such that the gaseous medium acts as an effective headspace for agitation of the formulation. The formulation comprises an aqueous medium, a drug in solid particulate form in a therapeutically effective amount suspended in the medium, and one or more wetting and/or suspending agents in an amount effective to provide controlled flocculation of the drug, at least one ingredient of the formulation being susceptible to oxidative degradation.

US Patent:

20030114430, Jun 19, 2003

Filed:

Aug 21, 2002

Appl. No.:

10/225320

Inventors:

Steven MacLeod - Portage MI, US
Lloyd Fox - Richland MI, US
Neal Adams - Kalamazoo MI, US
David Salvat - Marcellus MI, US

International Classification:

A61K031/56
A61K031/57
A61K009/14

US Classification:

514/177000, 514/182000, 424/489000

Abstract:

A parenterally deliverable composition is provided, comprising an aqueous medium having dispersed therein, in solid particulate form, a steroidal drug in a therapeutically effective amount. The aqueous medium comprises one or more wetting and/or suspending agents in an amount effective to provide controlled flocculation of the drug, at least one of the wetting and/or suspending agents being susceptible to oxidative degradation. The composition further comprises, as a component thereof or as an adjunct thereto, means for protecting the oxidative degradation susceptible agent from oxidative degradation.

US Patent:

20090036404, Feb 5, 2009

Filed:

Jul 28, 2008

Appl. No.:

12/180694

Inventors:

Steven K. MacLeod - Henrietta NY, US

International Classification:

A61K 31/715
A61P 27/02

US Classification:

514 54

Abstract:

Ophthalmic composition including a carboxyl-modified fructan or a salt thereof. The ophthalmic composition can be used in an eye care product or a contact lens care product such as a contact lens packaging solution or contact lens disinfecting solution.

US Patent:

20090092575, Apr 9, 2009

Filed:

Oct 7, 2008

Appl. No.:

12/246522

Inventors:

Steven K. MacLeod - Henrietta NY, US

International Classification:

A01N 37/52
A61K 31/195
A01P 1/00

US Classification:

424 7804, 514566, 514635

Abstract:

The invention is directed to an ophthalmic composition comprising a disuccinate of formula I or a corresponding salt thereof;wherein Ris selected from hydrogen, alkyl or —C(O)alkyl, the alkyl having one to twelve carbons and optionally one or more oxygen atoms, A is a methylene group or an oxyalkylene group, and n is from 2 to 8. The ophthalmic composition also includes a cationic antimicrobial component and a tonicity agent, wherein the tonicity agent provides for an osmolality of the composition from 200 mOs/kg to 420 mOsm/kg.

US Patent:

20090304811, Dec 10, 2009

Filed:

May 19, 2009

Appl. No.:

12/468136

Inventors:

Erning Xia - Penfield NY, US
Michael E. Allen - Webster NY, US
Steven K. MacLeod - Henrietta NY, US
Tammy J. Kleiber - Rochester NY, US
Graig M. Cody - Scottsville NY, US

International Classification:

A61K 33/40
A61K 33/22
C11D 3/04

US Classification:

424616, 424613, 510115

Abstract:

A pharmaceutical formulation that is effective in adversely affecting the viability of microorganisms or in inhibiting their growth and that provides better safety and/or comfort to the users comprises a polysaccharide, a source of hydrogen peroxide, and an anti-oxidant. The formulation can further comprise a chelating agent and/or an ophthalmically active agent for treating or controlling a disease or disorder of the eye. The formulation may be used to treat, clean, disinfect, store, wet, or rewet contact lenses.

US Patent:

20100247666, Sep 30, 2010

Filed:

Mar 1, 2010

Appl. No.:

12/714577

Inventors:

Steven K. MacLeod - Henrietta NY, US
Daniel J. Stein - Rochester NY, US
James Donald Hayes - Tampa FL, US
Donald L. Herber - Tampa FL, US

International Classification:

A61K 9/50
A61K 47/30

US Classification:

424501, 5147721

Abstract:

A process for producing a pharmaceutical suspension that comprises an active pharmaceutical ingredient (“API”) having low solubility, the process comprises: (a) preparing a first solution comprising a carboxy-containing vinyl polymer and a solvent; and (b) adding a compound of the API to said first solution under conditions of high-shear mixing for a time from about 5 minutes to about 5 hours, said compound being soluble in said solvent, thereby producing a suspension of particles of said API in a composition comprising said carboxy-containing vinyl polymer; wherein a concentration of said API in said suspension is higher than a solubility of said API in said solvent. The present invention also provides a suspension produced by such process.

US Patent:

20150038439, Feb 5, 2015

Filed:

Oct 21, 2014

Appl. No.:

14/519776

Inventors:

Steven K. MacLeod - Henrietta NY, US
Daniel J. Stein - Rochester NY, US
James Donald Hayes - Tampa FL, US
Donald L. Herber - Tampa FL, US

International Classification:

A61K 47/32
A61K 31/573
A61K 9/10
A61K 31/4709
A61K 31/196
A61K 9/14
A61K 31/55
A61K 31/7052

US Classification:

514 29, 51421711, 514180, 514300, 514567, 424489

Abstract:

A process for producing a pharmaceutical suspension that comprises an active pharmaceutical ingredient (“API”) having low solubility, the process comprises: (a) preparing a first solution comprising a carboxy-containing vinyl polymer and a solvent; and (b) adding a compound of the API to said first solution under conditions of high-shear mixing for a time from about 5 minutes to about 5 hours, said compound being soluble in said solvent, thereby producing a suspension of particles of said API in a composition comprising said carboxy-containing vinyl polymer; wherein a concentration of said API in said suspension is higher than a solubility of said API in said solvent. The present invention also provides a suspension produced by such process.